Combining Immunotherapy Agents in NSCLC: Is MYSTIC a Misstep? Combining Immunotherapy Agents in NSCLC: Is MYSTIC a Misstep?
Though they have received a lot of hype as the heir apparent in lung cancer therapy, the early signals on combining immunotherapies are not reassuring, cautions Dr Jack West.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Hematology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer